title: Impact of the national venous thromboembolism risk assessment tool in secondary care in England: retrospective population-based database study.
abstract: Venous thromboembolism (VTE) is a common and important cause of death in hospital patients. We therefore investigated possible associations between the introduction of the compulsory national VTE risk assessment tool in England in 2010 and patient outcomes. A retrospective database study, using data from the Health and Social Care Information Centre and Office of National Statistics, was undertaken. The main outcome measures were VTE-related secondary diagnosis rates, 30-day and 90-day readmission rates and mortality rates. The observed mean VTE-related secondary diagnosis rate for 2011-2012 was 91% of the rate estimated from a linear regression model of the data for 2006-2007 to 2010-2011 (P = 0.001). Similarly, the observed mean 30-day VTE-related readmission rate for 2011 was 96% of the estimated rate (P = 0.067) and the observed mean 90-day VTE-related readmission rate for 2011 was 96% of the estimated rate (P = 0.022). The observed annual VTE-related national mortality rate was 91% of the estimated rate for 2011 and 92% of the estimated rate for 2012. This study shows a reduction in VTE-related secondary diagnoses and readmissions among adults admitted to hospital, and a reduction in VTE-related population mortality, since the introduction of a national VTE risk assessment screening tool in England. Despite some study limitations, this suggests that the concerted effort made by NHS England to improve prevention of hospital-acquired VTE has been successful.
authors.affiliation: aDepartment of Economics, City University London, London bHealth Outcomes Department, Sanofi, Guildford, Surrey cKing's College, London and Guy's and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Catterick
authors.forename: Beverly J
authors.initials: BJ
authors.lastname: Hunt
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D004739:England; D005260:Female; D006801:Humans; D008297:Male; D010359:Patient Readmission / Q000706:statistics & numerical data*; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D018570:Risk Assessment / Q000706:statistics & numerical data*; D012307:Risk Factors; D063127:Secondary Health Care / Q000706:statistics & numerical data*; D016019:Survival Analysis; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology
chemical_list: D000925:Anticoagulants